Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MACROGENICS INCMGNX · Entity 6104 | Director | May 13, 2021 | May 18, 2021 |
| Zymeworks BC Inc.ZYME · Entity 12038 | Director · Chair, President & CEO | January 15, 2022 | January 18, 2022 |
| Zymeworks Inc.ZYME · Entity 4458 | Director · Chair & CEO | January 12, 2026 | January 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MACROGENICS INC
Report date May 13, 2021 · Filed May 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.88 · Expires 2031-05-13 | Direct | 15,000 |
Reported balance
After 2021-05-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-13 · Grant · Acquired 15,000 · Balance 15,000 F1: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.
Zymeworks BC Inc.
Report date January 15, 2022 · Filed January 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.97 · Expires 2032-01-14 | Direct | 500,000 |
Reported balance
After 2022-01-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-15 · Grant · Acquired 500,000 · Balance 500,000 F1: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date.
Zymeworks Inc.
Report date January 12, 2026 · Filed January 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 226,842 |
Ending reported balance
After 2026-01-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-12 · Exercise / conversion · Acquired 64,000 · Balance 257,266 F1: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 10, 2025. Row 2 · 2026-01-12 · Sale · Disposed 30,424 · Balance 226,842 F2: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.49 to $23.05, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 128,000 |
Reported balance
After 2026-01-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-12 · Exercise / conversion · Disposed 64,000 · Balance 128,000 F4: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F5: The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 144,000 |
Reported balance
After 2026-01-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-12 · Grant · Acquired 144,000 · Balance 144,000 F4: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F7: RSUs vest in four equal annual installments beginning on first anniversary of grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.16 · Expires 2036-01-11 | Direct | 216,000 |
Reported balance
After 2026-01-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-12 · Grant · Acquired 216,000 · Balance 216,000 F6: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. |
| Performance Stock UnitSEC Table II · derivative / convertible security | Direct | 222,000 |
Reported balance
After 2026-01-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-01-12 · Grant · Acquired 222,000 · Balance 222,000 F8: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 111,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. The PSUs will only vest at the end of the three-year performance period if the reporting person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, F9: (Continued from footnote 8) except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 10, 2025.
F2: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.49 to $23.05, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
F5: The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date.
F6: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.
F7: RSUs vest in four equal annual installments beginning on first anniversary of grant date.
F8: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 111,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. The PSUs will only vest at the end of the three-year performance period if the reporting person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals,
F9: (Continued from footnote 8) except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 12, 2026 Filed Jan 12, 2026 19:07 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantPerformance Stock Unit · Derivative | 222,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010790 · ownership.xml · derivative · entry 6 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,000 Underlying: Common Stock · 222,000 shares Expires not disclosed F8 · derivative.exercise_price: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 111,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. The PSUs will only vest at the end of the three-year performance period if the reporting person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, F9 · derivative.exercise_price: (Continued from footnote 8) except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control). F8 · derivative.exercise_date: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 111,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. The PSUs will only vest at the end of the three-year performance period if the reporting person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, F9 · derivative.exercise_date: (Continued from footnote 8) except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control). F8 · derivative.expiration_date: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 111,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. The PSUs will only vest at the end of the three-year performance period if the reporting person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, F9 · derivative.expiration_date: (Continued from footnote 8) except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control). Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 19:07 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantRestricted Stock Unit · Derivative | 144,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010790 · ownership.xml · derivative · entry 5 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,000 Underlying: Common Stock · 144,000 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F7 · derivative.exercise_date: RSUs vest in four equal annual installments beginning on first anniversary of grant date. F7 · derivative.expiration_date: RSUs vest in four equal annual installments beginning on first anniversary of grant date. Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 19:07 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 216,000 | $0.00 Strike: $23.16 | $0.00 |
DisclosureSEC source: 0001193125-26-010790 · ownership.xml · derivative · entry 4 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,000 Underlying: Common Stock · 216,000 shares Expires 2036-01-11 F6 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 19:07 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionRestricted Stock Unit · Derivative | 64,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010790 · ownership.xml · derivative · entry 3 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,000 Underlying: Common Stock · 64,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F5 · derivative.exercise_date: The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date. F5 · derivative.expiration_date: The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date. Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 19:07 UTC | Zymeworks Inc. ZYME · Entity 4458 | SaleCommon Stock | 30,424 | $22.67 | $689,818.56 |
DisclosureSEC source: 0001193125-26-010790 · ownership.xml · nonDerivative · entry 2 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,842 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.49 to $23.05, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 19:07 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionCommon Stock | 64,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010790 · ownership.xml · nonDerivative · entry 1 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,266 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 10, 2025. Read SEC document |
| January 05, 2026 Filed Jan 5, 2026 20:20 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionRestricted Stock Unit · Derivative | 66,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-003097 · ownership.xml · derivative · entry 6 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,668 Underlying: Common Stock · 66,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F7 · derivative.exercise_date: The RSUS were granted on January 5, 2024 and vest in three equal annual installments beginning on the first anniversary of January 5, 2024. F7 · derivative.expiration_date: The RSUS were granted on January 5, 2024 and vest in three equal annual installments beginning on the first anniversary of January 5, 2024. Read SEC document |
| January 05, 2026 Filed Jan 5, 2026 20:20 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionRestricted Stock Unit · Derivative | 47,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-003097 · ownership.xml · derivative · entry 5 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,668 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on the first anniversary of January 5, 2023. F6 · derivative.expiration_date: The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on the first anniversary of January 5, 2023. Read SEC document |
| January 05, 2026 Filed Jan 5, 2026 20:20 UTC | Zymeworks Inc. ZYME · Entity 4458 | SaleCommon Stock | 31,686 | $25.10 | $795,220.37 |
DisclosureSEC source: 0001193125-26-003097 · ownership.xml · nonDerivative · entry 4 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,266 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.715 to $25.84, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 05, 2026 Filed Jan 5, 2026 20:20 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionCommon Stock | 66,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-003097 · ownership.xml · nonDerivative · entry 3 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Represents shares of common stock issued upon vesting of one third of the RSUs granted on January 5, 2024. Read SEC document |
| January 05, 2026 Filed Jan 5, 2026 20:20 UTC | Zymeworks Inc. ZYME · Entity 4458 | SaleCommon Stock | 22,657 | $25.10 | $568,620.46 |
DisclosureSEC source: 0001193125-26-003097 · ownership.xml · nonDerivative · entry 2 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,286 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.715 to $25.84, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 05, 2026 Filed Jan 5, 2026 20:20 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionCommon Stock | 47,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-003097 · ownership.xml · nonDerivative · entry 1 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 5, 2023. Read SEC document |
| December 22, 2025 Filed Dec 22, 2025 17:52 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionRestricted Stock Unit · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-329028 · ownership.xml · derivative · entry 3 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2025-12-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUS vested on December 22, 2025. F5 · derivative.expiration_date: The RSUS vested on December 22, 2025. Read SEC document |
| December 22, 2025 Filed Dec 22, 2025 17:52 UTC | Zymeworks Inc. ZYME · Entity 4458 | SaleCommon Stock | 47,528 | $27.02 | $1,284,311.12 |
DisclosureSEC source: 0001193125-25-329028 · ownership.xml · nonDerivative · entry 2 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,275 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.83 to $27.16 inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 22, 2025 Filed Dec 22, 2025 17:52 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-329028 · ownership.xml · nonDerivative · entry 1 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares of common stock issued upon vesting of restricted stock units ("RSUs") granted on December 22, 2022. Read SEC document |
| January 10, 2025 Filed Jan 10, 2025 17:58 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantRestricted Stock Unit · Derivative | 192,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-004336 · ownership.xml · derivative · entry 2 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,000 Underlying: Common Stock · 192,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of Issuer's common stock. F3 · derivative.exercise_date: RSUs vest in three equal annual installments beginning on first anniversary of grant date. F3 · derivative.expiration_date: RSUs vest in three equal annual installments beginning on first anniversary of grant date. Read SEC document |
| January 10, 2025 Filed Jan 10, 2025 17:58 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 288,000 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0000950170-25-004336 · ownership.xml · derivative · entry 1 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 288,000 Underlying: Common Stock · 288,000 shares Expires 2035-01-09 F1 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| January 06, 2025 Filed Jan 6, 2025 20:34 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionRestricted Stock Unit · Derivative | 66,666 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-002497 · ownership.xml · derivative · entry 6 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,334 Underlying: Common Stock · 66,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F7 · derivative.exercise_date: The RSUS were granted on January 5, 2024 and vest in three equal annual installments beginning on the first anniversary of January 5, 2024. F7 · derivative.expiration_date: The RSUS were granted on January 5, 2024 and vest in three equal annual installments beginning on the first anniversary of January 5, 2024. Read SEC document |
| January 06, 2025 Filed Jan 6, 2025 20:34 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionRestricted Stock Unit · Derivative | 47,666 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-002497 · ownership.xml · derivative · entry 5 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,668 Underlying: Common Stock · 47,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on the first anniversary of January 5, 2023. F6 · derivative.expiration_date: The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on the first anniversary of January 5, 2023. Read SEC document |
| January 06, 2025 Filed Jan 6, 2025 20:34 UTC | Zymeworks Inc. ZYME · Entity 4458 | SaleCommon Stock | 33,406 | $14.92 | $498,554.48 |
DisclosureSEC source: 0000950170-25-002497 · ownership.xml · nonDerivative · entry 4 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,803 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.44 to $15.14, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 06, 2025 Filed Jan 6, 2025 20:34 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionCommon Stock | 66,666 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-002497 · ownership.xml · nonDerivative · entry 3 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Represents shares of common stock issued upon vesting of one third of the RSUs granted on January 5, 2024. Read SEC document |
| January 06, 2025 Filed Jan 6, 2025 20:34 UTC | Zymeworks Inc. ZYME · Entity 4458 | SaleCommon Stock | 23,885 | $14.92 | $356,462.13 |
DisclosureSEC source: 0000950170-25-002497 · ownership.xml · nonDerivative · entry 2 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,543 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.44 to $15.14, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 06, 2025 Filed Jan 6, 2025 20:34 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionCommon Stock | 47,666 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-002497 · ownership.xml · nonDerivative · entry 1 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 5, 2023. Read SEC document |
| January 08, 2024 Filed Jan 8, 2024 18:23 UTC | Zymeworks Inc. ZYME · Entity 4458 | SaleCommon Stock | 5,706 | $11.22 | $63,996.21 |
DisclosureSEC source: 0000950170-24-003099 · ownership.xml · nonDerivative · entry 3 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,762 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.49 to $11.58, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 18:23 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantRestricted Stock Unit · Derivative | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-003099 · ownership.xml · derivative · entry 6 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires not disclosed F5 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F8 · derivative.exercise_date: The RSUs vest in three equal annual installments beginning on January 5, 2025. F8 · derivative.expiration_date: The RSUs vest in three equal annual installments beginning on January 5, 2025. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 18:23 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $10.56 | $0.00 |
DisclosureSEC source: 0000950170-24-003099 · ownership.xml · derivative · entry 5 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2034-01-04 F7 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 18:23 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionRestricted Stock Unit · Derivative | 47,666 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-003099 · ownership.xml · derivative · entry 4 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,334 Underlying: Common Stock · 47,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on January 5, 2024. F6 · derivative.expiration_date: The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on January 5, 2024. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 18:23 UTC | Zymeworks Inc. ZYME · Entity 4458 | SaleCommon Stock | 18,198 | $10.65 | $193,848.74 |
DisclosureSEC source: 0000950170-24-003099 · ownership.xml · nonDerivative · entry 2 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,468 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.55 to $10.845, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 18:23 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionCommon Stock | 47,666 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-003099 · ownership.xml · nonDerivative · entry 1 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 5, 2023. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 20:00 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantRestricted Stock Unit · Derivative | 143,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-001217 · doc4.xml · derivative · entry 2 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,000 Underlying: Common Stock · 143,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs vest in three equal annual installments beginning on January 5, 2024. F3 · derivative.expiration_date: The RSUs vest in three equal annual installments beginning on January 5, 2024. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 20:00 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 215,000 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0000899243-23-001217 · doc4.xml · derivative · entry 1 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 215,000 shares Expires 2033-01-04 F1 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| December 22, 2022 Filed Dec 23, 2022 19:30 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantRestricted Stock Unit · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-039328 · doc4.xml · derivative · entry 1 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2025-12-22 F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vest on December 22, 2025. F2 · derivative.expiration_date: The RSUs vest on December 22, 2025. Read SEC document |
| January 15, 2022 Filed Jan 18, 2022 06:25 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $14.97 | $0.00 |
DisclosureSEC source: 0000899243-22-002069 · doc4.xml · derivative · entry 1 Galbraith Kenneth · CIK 0001567045 · Director · Chair, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Shares · 500,000 shares Expires 2032-01-14 F1 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| May 13, 2021 Filed May 18, 2021 01:20 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $28.88 | $0.00 |
DisclosureSEC source: 0001125345-21-000072 · wf-form4_162130080622593.xml · derivative · entry 1 Galbraith Kenneth · CIK 0001567045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 20:44 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionStock Option (right to buy) · Derivative | 6,924 | $0.00 Strike: $20.15 | $0.00 |
DisclosureSEC source: 0001125345-20-000133 · wf-form4_159977067917588.xml · derivative · entry 6 Galbraith Kenneth · CIK 0001567045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,924 shares Expires 2024-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 20:44 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionStock Option (right to buy) · Derivative | 13,849 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001125345-20-000133 · wf-form4_159977067917588.xml · derivative · entry 5 Galbraith Kenneth · CIK 0001567045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,849 shares Expires 2023-10-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 33.33% of the option became exercisable on October 9, 2014, and the remainder of the option vested in substantially equal annual installments. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 20:44 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 6,924 | $27.11 | $187,709.64 |
DisclosureSEC source: 0001125345-20-000133 · wf-form4_159977067917588.xml · nonDerivative · entry 4 Galbraith Kenneth · CIK 0001567045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This transaction was executed in multiple trades at prices ranging from $26.96 to $27.22. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staffof the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 20:44 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 6,924 | $20.15 | $139,518.60 |
DisclosureSEC source: 0001125345-20-000133 · wf-form4_159977067917588.xml · nonDerivative · entry 3 Galbraith Kenneth · CIK 0001567045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 20:44 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 13,849 | $27.11 | $375,446.39 |
DisclosureSEC source: 0001125345-20-000133 · wf-form4_159977067917588.xml · nonDerivative · entry 2 Galbraith Kenneth · CIK 0001567045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This transaction was executed in multiple trades at prices ranging from $26.96 to $27.22. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staffof the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 20:44 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 13,849 | $16.00 | $221,584.00 |
DisclosureSEC source: 0001125345-20-000133 · wf-form4_159977067917588.xml · nonDerivative · entry 1 Galbraith Kenneth · CIK 0001567045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2020 Filed May 15, 2020 20:36 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $24.97 | $0.00 |
DisclosureSEC source: 0001125345-20-000089 · wf-form4_158957498839484.xml · derivative · entry 1 Galbraith Kenneth · CIK 0001567045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-05-14 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant. Read SEC document |
| May 16, 2019 Filed May 20, 2019 21:49 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001125345-19-000077 · wf-form4_155838896990746.xml · derivative · entry 1 Galbraith Kenneth · CIK 0001567045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-05-16 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| May 17, 2018 Filed May 21, 2018 20:55 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $21.34 | $0.00 |
DisclosureSEC source: 0001125345-18-000075 · wf-form4_152693609377614.xml · derivative · entry 1 Galbraith Kenneth · CIK 0001567045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-05-17 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant. Read SEC document |
| May 18, 2017 Filed May 22, 2017 23:02 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $19.57 | $0.00 |
DisclosureSEC source: 0001125345-17-000078 · wf-form4_149549412514927.xml · derivative · entry 1 Galbraith Kenneth · CIK 0001567045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.